BIOSIMILARS AFTER ACTAVIS: SIMILAR CONSIDERATIONS, SIMILAR RESULTS
Author: Jason M. Premus On September 3, 2015, the United States watched as the first “generic-like” biologic drug entered the market ushering in a new era for the pharmaceutical industry. In tow, the hopes of the American people and the promise of lower-priced, life-altering medication. This entry comes at a time when the lower courts… continue reading